ClinicalTrials.gg
CompletedNCT06141577Updated Nov 21, 2023

A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects

A Phase 1 interventional study of UI059 and UIC202201 in GERD, sponsored by Korea United Pharm. Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
49th of 52
8 · median 54
Started
2023
with 4 others
Phase 1
21 of 71
2 open now
Registered
56th of 71
by date
Lead sponsor
3 of 71
Korea United Pharm. Inc.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 49th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 in phase 1, and was the 56th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A randomized, open-label, multiple-dose crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

03

Conditions studied

  • GERD
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy adult volunteers aged 19 and above.
  • For males, a weight of 50.0 kg or more, and for females, a weight of 45.0 kg or more, with a (BMI) between 18.0 kg/m2 and 30.0 kg/m2.

BMI(kg/m2)=Weight(kg)/height(m)2

  • No congenital or chronic diseases requiring treatment, and no pathological symptoms or findings based on internal medicine examination.
  • Those who were determined to be suitable subjects for clinical trials as a result of tests such as clinical laboratory tests, vital signs, physical examination (physical examination), and 12-lead
  • Negative for H. pylori antibodies
  • After receiving detailed explanations about the clinical trial and fully understanding, participants voluntarily decide to participate and provide written consent to adhere to the subject compliance requirements throughout the trial period.

Exclusion criteria

Exclusion Criteria:

  • Current or past medical history of conditions involving the liver, kidneys, nervous system, mental health, respiratory system, endocrine system, blood disorders, tumors, genitourinary system, cardiovascular system, digestive system, musculoskeletal system, etc., and in addition:

    • currently receiving antiretroviral drugs (rilpivirine, atazanavir, nelfinavir)
    • liver disorders
    • kidney disorders
  • History of gastrointestinal conditions (Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy or hernia repair) that may affect the absorption of the drug.
  • Pregnant (positive Urine-HCG) or lactating for female participants
  • Have a history of reactions (such as anaphylaxis or angioedema) or clinically significant hypersensitivity reactions to drugs, , or other substances, including medications containing the active ingredients of the investigational drug, additives, and other drugs (such as aspirin, penicillin antibiotics, macrolide antibiotics).
  • Have clinically significant findings on the 12-lead during screening, including:

    • > 450 ms for males or > 470 ms for females.
    • PR interval > 200 ms.
    • QRS duration > 120 ms.
  • Showing the following results in clinical trial laboratory tests during screening:

    • liver function assessment: , ALT, ALP, γ-GTP, and total exceeding twice the .
    • Blood creatinine levels outside the reference range or calculated estimated (eGFR) using the CKD-EPI formula less than 60 mL/min/1.73m2.
  • History of drug abuse or individuals who have shown a positive reaction for abused substances in a urine drug test.
  • During screening, exhibit vital signs measured after at least 3 minutes of rest in a seated position with systolic blood pressure (SBP) ≥ 150 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or a heart rate (HR) ≤ 40 bpm or ≥ 100 bpm.
  • Have an abnormal diet that could affect the absorption, distribution, metabolism, or excretion of the investigational drug, or individuals who consume foods that could impact drug metabolism.
  • Administered any prescription medications or herbal products that could influence the characteristics of the investigational drug within 2 weeks before the first dose or any OTC drugs or vitamin supplements within 10 days before the first dose. (If there is no effect on the pharmacokinetic properties of this investigational drug, the investigator may participate in the clinical trial at the discretion of the investigator.)
  • Administer drugs that induce or inhibit drug-metabolizing enzymes, such as barbiturates, within 1 month before the first administration date.
  • Participated in other clinical trials within 6 months prior to the first administration date (The endpoint for determining the end of participation in another clinical trial is considered one day after the last administration in that trial.)
  • Those who have consistently consumed alcohol in excess of 21 units/week (1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the first administration date or who are unable to abstain from alcohol from the time of written consent to the time of PSV.
  • Smokers who smoke more than 10 cigarettes on average per day within 3 months before the first administration date and those who are unable to quit smoking from 24 hours before each administration until the time of the last blood collection
  • Consumed food containing grapefruit or cannot refrain from eating it from 48 hours before the first administration until the time of PSV
  • Those who consumed caffeine-containing foods (coffee, green tea, black tea, carbonated drinks, coffee milk, tonic drinks, etc.) during the period from 24 hours before administration to the time of the last blood collection, or who cannot refrain from consuming them.
  • Those who engaged in vigorous exercise exceeding the level of daily life during the period from 48 hours before the first administration to the time of PSV, or who cannot refrain from vigorous exercise
  • From the time of the subject's written consent until 2 weeks after the last administration of the investigational drug, even if the person, spouse, or partner is planning to become pregnant or is not planning to become pregnant, a recognized method of (e.g., administration of contraceptives, implantation or intrauterine device, sterilization procedure (vasectomy), not using surgical resection, tubal ligation, etc.) or blocking methods (combined use of spermicides, condoms, contraceptive diaphragms, vaginal sponges, or cervical caps)
  • Judged by the investigator to be unsuitable for participation in clinical trials due to reasons other than the above selection/exclusion criteria
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    UI059

    Drug: UI059

  • Active comparator
    UIC202201

    Drug: UIC202201

Interventions

  • DrugUI059

    take UI059 1cap/day for 7 days

    Also known as: Test

  • DrugUIC202201

    take UIC202201 1cap/day for 7 days

    Also known as: Reference

06

What researchers measure

Primary outcomes

  1. AUCtau,ss

    Area under the plasma concentration-time curve within a dosing interval at steady state

    Time frame: Day 1: 0~24hours / Day 5, 6: 0hours / Day 7: 0~24hours

  2. Percent decrease from baseline in integrated gastric acidity

    Percent decrease from baseline in integrated gastric acidity for 24 hours after multiple(7th dose) administrations

    Time frame: Day -1~Day 1, Day 1~Day 2, Day 7

07

Study locations

1 site
  • Chungbuk national university hospital
    Cheongju-si, Chungcheongbuk-do 28644, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Nov 2023, 0 months.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 0 months is below that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 21, 2023
StartActual
Oct 8, 2023
Primary completionActual
Nov 7, 2023
CompletionActual
Nov 15, 2023
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06141577
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Oct 8, 2023
Primary completion
Nov 7, 2023
Completion
Nov 15, 2023
Last update
Nov 21, 2023

Study contacts

Minkyu Park, Dr
principal investigator · Chungbuk National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UI059

Start the discussion